DUBLIN–(BUSINESS WIRE)– <\/p>\n
Research and Markets (http:\/\/www.researchandmarkets.com\/research\/c9kszn\/parkinsons_diseas<\/a>) has announced the addition of GlobalData ‘s new report “Parkinson’s Disease Therapeutics – Global Drug Forecasts and Treatment Analysis to 2020″ to their offering. <\/p>\n Parkinson’s Disease (PD) Therapeutics Market is Forecast to Show Slow Growth to 2020 <\/p>\n In 2011, the global Parkinson’s Disease (PD) therapeutics market, which includes the key markets of the US, Japan, Germany, the UK, France, Italy, Spain, Brazil, China, India and Russia was estimated to be worth $2,992m. During the period 2002-2011, the global PD therapeutics market grew at a Compound Annual Growth Rate (CAGR) of 5.8%. GlobalData analysis shows that the market size was primarily driven by two key parameters: the increase in PD prevalence due to the increase in the aging population in the 11 key markets and the increasing cost of therapy. <\/p>\n In 2011, the market registered a decline in the market valuations due to the entry of generics for Mirapex (pramipexole) and higher preference for generic ropinirole. The market declined from $3,499m in 2010 to $2,992m in 2011. The US was leading PD therapeutics market, with an estimated value of $1,046m in 2011 and a market share of 35%. Japan was the second biggest market, with an estimated value of $542m and an 18.1% market share, followed by Germany with a market share of 15.6%. <\/p>\n The global PD therapeutics market is primarily served by levodopa, dopamine agonists, Monoamine Oxidase Inhibitors (MAO-BI) and Catechol-O-Methyltransferase (COMT) inhibitors. The market is dominated by branded products such as Boehringer Ingelheim’s Mirapex\/Mirapexin \/ Sifrol \/ Mirapex ER \/ Mirapexin ER (pramipexole), GlaxoSmithKline’s (GSK) Requip\/Requip XL (ropinirole), Orion \/ Novartis’ Stalevo\/Comtan (carbidopa\/levodopa\/entacapone) and Teva\/Lundbeck’s Azilect\/Agilect (rasagiline). In addition, a large number of generics are also available in this market. <\/p>\n Key Topics Covered: <\/p>\n 1 List of Tables and Figures <\/p>\n 2 Parkinson’s Disease Therapeutics – Disease Overview <\/p>\n 3 Parkinson’s Disease Therapeutics – Market Characterization <\/p>\n<\/p>\n Read the rest here: Source: DUBLIN–(BUSINESS WIRE)– Research and Markets (http:\/\/www.researchandmarkets.com\/research\/c9kszn\/parkinsons_diseas<\/a>) has announced the addition of GlobalData ‘s new report “Parkinson’s Disease Therapeutics – Global Drug Forecasts and Treatment Analysis to 2020″ to their offering. Parkinson’s Disease (PD) Therapeutics Market is Forecast to Show Slow … Continue reading
\nResearch and Markets: Parkinson's Disease Therapeutics – Parkinson's Disease (PD) Therapeutics Market is Forecast to …<\/a><\/p>\n
http:\/\/www.longevitymedicine.tv\/feed\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"